Thu, Apr 27, 2017
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Capital markets likely to stabilize during the second half of 2012

Thursday, August 09, 2012

Bailey McCann, Opalesque New York: Capital markets may start to stabilize according to research from Credit Suisse’s Asset Management division. The group released its Q3 2012 Alternatives Quarterly and discusses the outlook for alternatives in the second half. "Sluggish global growth and Eurozone concerns will continue to weigh on investor sentiment, but these worries have, to a visible extent, already been priced into the markets. Additionally, we see the outcomes of the June European Union (EU) summit and Mario Draghi’s recent statements as positive steps that confirm the willingness for necessary policy action in the region, " says Stefan Keitel, Global Chief Investment Officer for Asset Management and Private Banking.

Ahead of the stabilization, Keitel notes that the group has increased its allocation to equities after the expected market correction in March to May, as part of a real-asset strategy. They increasingly prefer the more countercyclical and lagging markets, specifically in the Eurozone over the defensive US and Swiss markets. They are also overweight in emerging market (including China, Korea and Russia) and UK equities.

He explains that in bonds, the group prefers high-yield and corporate bonds over high-grade government bonds, given a persistent cycle of negative yields and limited upside potential. Currencies are also likely to remain range bound, according to the report. "Turning to commodities, we maintain our strategic overweight position on gol......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Alternative asset firm YieldStreet surpasses $100m of loans funded in less than 8 quarters[more]

    Komfie Manalo, Opalesque Asia: Alternative asset investment platform YieldStreet reported that it has surpassed $100m in loans funded in less than eight quarters from accredited investors and single family offices. YieldStreet was founded by Milind Mehere and Michael Weisz. In a

  2. Investing - Investor appetite for high-growth IPOs to be tested, Apollo boosts fund's stock allowance for 'diamonds in the rough', Hedge funds uncertain over outlook for Hargreaves Lansdown[more]

    Investor appetite for high-growth IPOs to be tested From FT.com: The US listings market is poised for a busy week with deals that will test investors' appetite for high-growth - but lossmaking - companies. Eight new listings are scheduled for this week, the most since October of 2016,

  3. Hedge funds holding Puerto Rico bonds are looking at a long battle[more]

    Komfie Manalo, Opalesque Asia: Hedge funds which bought Puerto Rico's distressed debt bonds are facing the prospect of a long road ahead to recover their investments as the Caribbean island is attempting to use a U.S. Congress-approved rule that allows it to exploit a bankruptcy-like proceedings

  4. Other Voices: "Winner-take-all" dynamics and hedge fund investing[more]

    A growing stream of thinking in microeconomics is the concept of "winner-take-all" dynamics. The idea seems simple. A combination of networking economics and classic economies of scale creates situations where there are just a few dominant firms or economic agents who are able to capture significant

  5. Investing - How Chipotle's comeback attracted big data robots and value investors alike[more]

    From Forbes.com: When William Ackman's ailing hedge fund Pershing Square Capital Management bet $1 billion on shares in Chipotle Mexican Grill beginning in July 2016, the stakes couldn't have been higher. Pershing Square was reeling from what would eventually be a near $4 billion loss in drugmaker V